In this webinar, Dr. Eliaz presents groundbreaking research findings and practice-tested protocols to effectively manage Galectin-3, including the use of selective apheresis showing breakthrough results against life-threatening sepsis and other pro-inflammatory conditions. He will also discuss benefits, risks, and common misconceptions related to apheresis.
For more than 30 years, Isaac Eliaz, MD, MS, LAc, has investigated Galectin-3 and its role in inflammation, fibrosis, cancer, kidney injury, sepsis, and emerging therapeutic approaches.
Why do two patients with similar metabolic profiles sometimes respond so differently to the same GLP-1 medication? Galectin-3 may offer an important clue. This emerging biomarker provides insight into the inflammatory and fibrotic “metabolic terrain” that may influence GLP-1 treatment response.
Join functional medicine pioneer Dr. Tom O’Bryan, DC, CCN, DACBN, CIFM, as he shares breakthrough research, clinical strategies, and functional medicine frameworks to understand, diagnose, and effectively address the complex pathology of endotoxin exposure and its impacts on health span, longevity, and clinical outcomes. In today’s age, patients are presentingRead
Arguably, the most prominent ‘sleeper’ disease that contributes to 1 in every 2 to 3 hospital deaths is sepsis.1 Fueled by lipopolysaccharide (LPS)2— referred to clinically as endotoxin when it activates an immune response3— LPS was primarily viewed as an acute trigger of sepsis and systemic inflammatory response syndrome. Today,Read
Galectin-3 is emerging as a key biomarker and driver of inflammation, fibrosis and chronic disease. This review examines the clinical relevance of galectin-3 and the research behind modified citrus pectin as a promising integrative strategy for supporting brain, cardiovascular, renal and immune health.
MCP has demonstrated significant anticancer activity in vitro, in animal studies, and in clinical studies. Beyond its anticancer properties, MCP is shown to improve metal detoxification, immune function, cardiovascular function, and reduce fibrosis to the kidney, liver, and adipose tissue. Together, this body of evidence positions MCP as a promising, multi-targeted intervention with applications in oncology and chronic disease management.
Galectin-3 is increasingly recognized as a culprit biomarker and primary driver of inflammation, fibrosis, and chronic disease. Knowing how to test for and address this upstream alarmin protein is an emerging clinical competency that is quickly earning its place as a foundational strategy for optimal patient outcomes. This in-depth clinical guideRead
Over the last decade or so, research interest in the pro-inflammatory and pro-fibrotic immune protein galectin-3 (Gal-3) has skyrocketed. Today, thousands of published scientific papers—including longitudinal cohort studies—point to the driving role of galectin-3 in the pathogenesis of our most serious degenerative conditions, from chronic kidney disease and acute kidneyRead
In this video, Josh Helman, MD discusses the pathogenic mechanisms of the pro-inflammatory immune protein galectin-3 and its role in neurodegenerative diseases, biofilm formation, autoimmunity and other critical conditions. An expert in the fast-growing field of galectin-3 research, Dr. Helman shares key research findings, as well as clinical pearls onRead
